Opendata, web and dolomites

NEUcrest SIGNED

Training European Experts in Multiscale Studies of Neural Crest Development and Disorders: from Patient to Model Systems and Back again.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NEUcrest project word cloud

Explore the words cloud of the NEUcrest project. It provides you a very rough idea of what is the project "NEUcrest" about.

birth    gut    embryonic    understand    tumour    neurocristopathy    framework    creative    mutations    optimise    pharma    patients    strategies    vivo    derivatives    nc    candidate    drug    syndromes    training    caused    esrs    molecular    neucrest    takes    defects    academia    industry    crest    synergistic    environmental    melanoma    strategy    healthcare    clinical    regulation    interface    programs    tissue    heart    genetic    fundamentals    models    screening    discovery    integrative    group    diseases    health    clinic    network    reactivate    networking    initiation    neuroblastoma    of    neural    difficult    broad    biological    multidisciplinary    scientists    diverse    human    phenotyping    pleiotropic    public    therapeutics    networks    create    genetics    translational    cellular    functional    interdisciplinary    animal    improvements    clinicians    innovative    back    gene    cancers    cleftvpalate    genes    computational    adrenals    neurocristopathies    phenotypes    lineage    scientific    unified    disease    model    events    provides    causative   

Project "NEUcrest" data sheet

The following table provides information about the project.

Coordinator
INSTITUT CURIE 

Organization address
address: rue d'Ulm 26
city: PARIS
postcode: 75231
website: www.curie.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 4˙156˙404 €
 EC max contribution 4˙156˙404 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2019
 Funding Scheme MSCA-ITN-ETN
 Starting year 2019
 Duration (year-month-day) from 2019-11-01   to  2023-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INSTITUT CURIE FR (PARIS) coordinator 549˙604.00
2    UNIVERSITY OF EAST ANGLIA UK (NORWICH) participant 606˙345.00
3    NATIONAL UNIVERSITY OF IRELAND GALWAY IE (Galway) participant 549˙368.00
4    UNIVERSIDAD MIGUEL HERNANDEZ DE ELCHE ES (ELCHE) participant 501˙809.00
5    KING'S COLLEGE LONDON UK (LONDON) participant 303˙172.00
6    STEMCELL TECHNOLOGIES UK LTD UK (CAMBRIDGE) participant 303˙172.00
7    AZELEAD FR (MONTPELLIER) participant 274˙802.00
8    IMAGINE INSTITUT DES MALADIES GENETIQUES NECKER ENFANTS MALADES FONDATION FR (PARIS 15) participant 274˙802.00
9    ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM NL (ROTTERDAM) participant 265˙619.00
10    MEDIZINISCHE UNIVERSITAET WIEN AT (WIEN) participant 264˙207.00
11    TEL AVIV UNIVERSITY IL (TEL AVIV) participant 263˙500.00

Map

 Project objective

Neurocristopathies caused by defects in the neural crest (NC) encompass a broad group of diseases from birth defects (cleftvpalate) to complex syndromes affecting systems such as heart, gut and adrenals. Because NC derivatives are diverse, mutations affecting this lineage can lead to pleiotropic phenotypes making it difficult to understand the causative events. Furthermore, NC-derived cancers, (e.g. melanoma and neuroblastoma) reactivate embryonic programs during tumour initiation. Our aim is to create a unique interdisciplinary network of scientists and clinicians partners from academia, healthcare, industry and the public sector with experience in gene discovery, genetics, functional studies and in vivo phenotyping aimed at training creative and innovative ESRs to study the overall genetic, molecular and environmental regulation of NC tissue in human health. To study each of complex aspects of NC and tumour formation, NEUcrest provides a synergistic framework for comprehensive analysis of candidate genes and biological processes, from patients to model systems to pharma and back to the clinic. With the aim to develop a unified strategy to identify new genetic and environmental factors that contribute to disease and to develop new drug targets for therapeutics, ESRs will address following scientific challenges: undertake novel gene discovery approaches; establish cellular/animal models of disease; establish integrative strategies for understanding neurocristopathies; optimise computational modelling of NC gene networks; establish translational strategies for drug screening in NC-related diseases; improve clinical management strategies of NC-disease and interface with patients and the public. Our training program takes into account training through research as well as multidisciplinary partnerships and networking opportunities. All together, this will improve our understanding of the fundamentals of neurocristopathy and contribute to improvements in healthcare.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NEUCREST" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NEUCREST" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

LIVE-I (2020)

Lightening and Innovating transmission for improving Vehicle: Environmental Impacts

Read More  

SuperCol (2020)

SuperCol: Rational design of super-selective and responsive colloidal particles for biomedical applications

Read More  

TACT (2020)

Targeted Anti-Cancer Therapies

Read More